Galderma has received a Complete Response Letter (CRL) from the FDA for Relfydess (relbotulinumtoxinA), its novel botulinum toxin formulation intended as a Botox alternative. The CRL indicates the agency requires additional data or clarification before approval can be granted, effectively blocking the product's U.S. market entry in the near term.
Regulatory
Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle
FDA rejects Galderma's new neuromodulator formulation; shares slide on failed market-entry bid.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Get the free Inside MedSpa brief by email
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
FDA Complete Response Letter blocks Relfydess market entry; Galderma's neuromodulator expansion stalls.
Relfydess was positioned as a differentiated neuromodulator with a potentially faster onset and longer duration than existing toxins, but the regulatory pathway proved more complex than anticipated. The setback underscores the high bar for new-entity botulinum toxin approvals and the entrenched competitive advantage of AbbVie's Botox and Galderma's own Dysport. For practices, this means no near-term disruption to toxin pricing or supply dynamics; the neuromodulator market remains dominated by two players with limited new competition on the horizon.
Source: original report ↗
Frequently asked questions
What is Relfydess and why did the FDA reject it?
Relfydess is Galderma's novel botulinum toxin formulation designed as a Botox alternative with potentially faster onset and longer duration. The FDA issued a Complete Response Letter (CRL), meaning the agency requires additional data or clarification before approval—effectively blocking U.S. market entry in the near term.
Will Relfydess rejection affect Botox pricing or supply?
No. The rejection means no near-term disruption to toxin pricing or supply dynamics. The neuromodulator market remains dominated by Botox (AbbVie) and Dysport (Galderma), with limited new competition on the horizon.
How hard is it to get FDA approval for a new botulinum toxin?
Very hard. Relfydess's rejection underscores the high regulatory bar for new-entity botulinum toxin approvals. The entrenched competitive advantage of existing players like Botox and Dysport makes market entry significantly more complex than anticipated.
What does a Complete Response Letter mean for a drug approval?
A Complete Response Letter (CRL) indicates the FDA cannot approve the drug in its current form and requires additional data, clarification, or further studies before resubmission. It effectively delays or blocks market entry until the company addresses the agency's concerns.
When might Relfydess become available if Galderma resubmits?
The timeline is unclear. Galderma must first gather additional data or clarification to address the FDA's concerns, then resubmit—a process that typically takes months to years depending on the complexity of the issues raised in the CRL.
Business information, not medical or legal advice. Verify product status at FDA.gov.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.